Cell motility as random motion: A review D Selmeczi, L Li, LII Pedersen, SF Nrrelykke, PH Hagedorn, S Mosler, ... The European Physical Journal-Special Topics 157 (1), 1-15, 2008 | 159 | 2008 |
Modeling oscillatory control in NF-κB, p53 and Wnt signaling B Mengel, A Hunziker, L Pedersen, A Trusina, MH Jensen, S Krishna Current opinion in genetics & development 20 (6), 656-664, 2010 | 78 | 2010 |
PAPD5/7 are host factors that are required for hepatitis B virus RNA stabilization H Mueller, A Lopez, P Tropberger, S Wildum, J Schmaler, L Pedersen, ... Hepatology 69 (4), 1398-1411, 2019 | 70 | 2019 |
Liver-targeted anti-HBV single-stranded oligonucleotides with locked nucleic acid potently reduce HBV gene expression in vivo H Javanbakht, H Mueller, J Walther, X Zhou, A Lopez, T Pattupara, ... Molecular Therapy-Nucleic Acids 11, 441-454, 2018 | 69 | 2018 |
miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer Y Pan, G Robertson, L Pedersen, E Lim, A Hernandez-Herrera, AC Rowat, ... Oncotarget 7 (18), 25930, 2016 | 68 | 2016 |
A kinetic model explains why shorter and less affine enzyme-recruiting oligonucleotides can be more potent L Pedersen, PH Hagedorn, MW Lindholm, M Lindow Molecular Therapy-Nucleic Acids 3, 2014 | 63 | 2014 |
A Wnt oscillator model for somitogenesis PB Jensen, L Pedersen, S Krishna, MH Jensen Biophysical journal 98 (6), 943-950, 2010 | 60 | 2010 |
Independent component and pathway-based analysis of miRNA-regulated gene expression in a model of type 1 diabetes CH Bang-Berthelsen, L Pedersen, T Fløyel, PH Hagedorn, T Gylvin, ... BMC genomics 12, 1-11, 2011 | 50 | 2011 |
Plasma proteome analysis of patients with type 1 diabetes with diabetic nephropathy AJ Overgaard, HG Hansen, M Lajer, L Pedersen, L Tarnow, P Rossing, ... Proteome science 8, 1-11, 2010 | 49 | 2010 |
Expression and localization of microRNAs in perinatal rat pancreas: role of miR-21 in regulation of cholesterol metabolism L Larsen, MW Rosenstierne, LW Gaarn, A Bagge, L Pedersen, ... PloS one 6 (10), e25997, 2011 | 39 | 2011 |
Identifying interactions in omics data for clinical biomarker discovery using symbolic regression NJ Christensen, S Demharter, M Machado, L Pedersen, M Salvatore, ... Bioinformatics 38 (15), 3749-3758, 2022 | 25 | 2022 |
Finding diabetic nephropathy biomarkers in the plasma peptidome by high‐throughput magnetic bead processing and MALDI‐TOF‐MS analysis HG Hansen, J Overgaard, M Lajer, F Hubalek, P Højrup, L Pedersen, ... PROTEOMICS–Clinical Applications 4 (8‐9), 697-705, 2010 | 21 | 2010 |
Dickkopf1-a new player in modelling the Wnt pathway L Pedersen, MH Jensen, S Krishna PLoS One 6 (10), e25550, 2011 | 17 | 2011 |
Comment on “Direct Measurement of the Oscillation Frequency in an Optical-Tweezers Trap by Parametric Excitation” L Pedersen, H Flyvbjerg Physical Review Letters 98 (18), 189801, 2007 | 11 | 2007 |
Oligonucleotides for inducing paternal UBE3A expression V Costa, M Hedtjärn, M Hoener, R Jagasia, MA Jensen, C Patsch, ... US Patent 10,494,633, 2019 | 10 | 2019 |
Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infection S Kammler, A Lopez, H Mueller, S Ottosen, L Pedersen US Patent 10,953,034, 2021 | 7 | 2021 |
Identifying suitable target regions and analyzing off-target effects of therapeutic oligonucleotides L Pedersen, PH Hagedorn, T Koch Oligonucleotide-Based Therapies: Methods and Protocols, 261-282, 2019 | 6 | 2019 |
Nucleic acid molecules for reduction of PAPD5 or PAPD7 mRNA for treating hepatitis B infection H Javanbakht, S Ottosen, L Pedersen, H Mueller US Patent 11,534,452, 2022 | 5 | 2022 |
Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infection S Kammler, A Lopez, H Mueller, S Ottosen, L Pedersen US Patent 11,484,546, 2022 | 5 | 2022 |
Oligonucleotides for reduction of pd-l1 expression L Pedersen, H Javanbakht, M Jackerott, S Ottosen, S Luangsay US Patent App. 15/458,800, 2017 | 5 | 2017 |